AAbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Work here?Claim your company
Industries
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, IL
Founded
1888
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$17B
Above
Industry Average
Funded Over
2 Rounds
AbbVie (ABBV) ranks 10th on Insider Monkey's list of best healthcare and insurance stocks to buy after the Democrats' November 3 midterm sweep. A total of 88 hedge funds back the stock. Healthcare shares rallied on expectations that a Democratic Congress could delay Medicaid cuts and restore enhanced Affordable Care Act subsidies. JPMorgan analysts warned that President Donald Trump's veto power could produce "legislative gridlock" rather than sweeping reform. AbbVie's third-quarter revenue rose 10.3% year over year to $17.404 billion. Skyrizi brought in $5.776 billion and Rinvoq $2.706 billion, while Humira revenue fell 31.2% to $683 million. Oncology revenue grew only 0.8%, and aesthetics revenue fell 1.4%.
AbbVie shares have returned 38.4% over the past twelve months, against 9.8% for the S&P 500. Management has now flagged a pressure that begins in 2027: a government-set price for the psychiatry drug Vraylar under the US Inflation Reduction Act (IRA). Management did not say how much of Vraylar's sales the price will affect. Vraylar sales rose 10.8% to $3.62 billion in fiscal 2025, and management expects $4.2 billion in fiscal 2026. AbbVie has faced this before. Sales of the cancer drug Imbruvica fell 26.1% in the third quarter of fiscal 2026, which management attributed to IRA pricing and competition. Total revenue still rose 10.3% in the quarter. The shares trade at 49.8 times trailing earnings, against 21.8 for the S&P 500.
AbbVie has agreed a global licensing deal with Nxera Pharma worth up to $1.37 billion. The deal covers an oral EP4 receptor agonist for inflammatory bowel disease (IBD). AbbVie gets worldwide rights to develop and commercialise the candidate. Nxera keeps certain co-funding and royalty interests. AbbVie is also expanding its UK research presence with a new Oxford facility focused on immunology, neuroscience, and oncology. The moves aim to refill a pipeline as older blockbusters such as Humira and Imbruvica decline. Analysts flag execution risk, given high research spending and debt.
IBM unveils its most advanced quantum computer in Chicago, marking a milestone for Illinois's Quantum future. Nov 06, 2026, 15:14 ET Hosted by the University of Chicago, IBM Quantum System Two is now operational at Hyde Park Labs and will be a prominent fixture of Illinois Quantum and Microelectronics Park (IQMP) upon the site's completion. IBM's first quantum computer in Illinois extends the company's industry and academic partnerships across the state, enabling the Illinois ecosystem and beyond to scale quantum algorithms and applications. CHICAGO, Nov. 6, 2026 /CNW/ - IBM (NYSE: IBM), the University of Chicago, the State of Illinois, and Illinois Quantum and Microelectronics Park (IQMP) today unveiled an IBM Quantum System Two in Chicago, IBM's first quantum computer in Illinois and the company's most advanced system available. Initially located at Hyde Park Labs and hosted by the University of Chicago, the system is fueled by IBM Quantum Nighthawk, the most powerful quantum chip IBM has ever built. Today, organizations across Illinois are already working with IBM to explore how quantum computing can scale to computationally difficult challenges. The new system aims to catalyze the state's robust ecosystem of scientists, universities, national laboratories, startups, and enterprises, many of whom are collaborating with IBM in Chicago within IQMP's National Quantum Algorithm Center (NQAC) to develop the next generation of algorithms and applications. As the anchor system of NQAC, which was established in 2024 by Illinois Governor JB Pritzker with IBM as a leading member, the new quantum computer will ultimately be moved to IQMP, a first-of-its-kind campus in Chicago currently being built to develop and scale quantum technology and microelectronics innovation. "IBM is proud to deploy our first quantum computer of IQMP - an IBM Quantum System Two. Today, it can deliver scientifically useful results to organizations across the state of Illinois and beyond," said Arvind Krishna, Chairman and CEO, IBM. "As IBM's first quantum computer in Illinois, the system's deployment marks a milestone for Illinois' quantum community and builds on IBM's partnerships across the state as we expand quantum research across academia and industries." "I want the next generation of breakthroughs to happen in Illinois and the jobs and opportunity that come with them to benefit the people of Illinois," said Governor JB Pritzker. "With the unveiling of IBM's Quantum System Two in Hyde Park, we are giving researchers and businesses the tool to turn big ideas into real-world solutions. With our growing partnership with IBM, we are building an industry that will give Illinoisans more career opportunities and build a future right here at home." "The presence of IBM's first quantum computer in Illinois, the company's most advanced system available, is a testament to what's possible when partners across government, industry and academia work together toward a shared vision," said Harley Johnson, CEO of the IQMP. "Today reflects the unique strength of Illinois' quantum ecosystem. We're thrilled to see IBM Quantum System Two at Hyde Park Labs while the Park is under construction, and we're more energized than ever to welcome it to the IQMP, where it will anchor the National Quantum Algorithm Center and further establish Illinois as the global destination for quantum innovation." "The deployment of IBM's Quantum System Two represents the culmination of a years-long partnership that brought together academia, government, and private industry to usher in a new generation of discovery. I am delighted that this machine is being unveiled here in Hyde Park, where our neighbors and community will have a view into the future," said University of Chicago President Paul Alivisatos. "IBM Quantum System Two brings another critical capability to Illinois' growing quantum ecosystem and showcases the collaboration that makes our state such a draw," said Illinois Economic Development Corporation President and CEO Christy George. "For companies developing quantum technologies and applications, access to advanced computing systems, leading researchers, and industry partners in one place is a powerful advantage. This investment strengthens Illinois' position as a destination for companies looking to innovate, grow, and help shape the future of quantum computing." This new IBM Quantum System Two advances IBM's mission to bring useful quantum computing to the world and extends the company's commitment to advancing Illinois as a global epicenter for quantum innovation. Since NQAC's founding, IBM has helped grow the center into a hub within Chicago where industry leaders work side-by-side with IBM researchers to build quantum applications that can scale alongside technical progress in the field. This includes NQAC Grand Challenge participants Deloitte and AbbVie, who are working with IBM and Northwestern University to build quantum molecular simulation approaches for researchers engaging in drug discovery. Other Grand Challenges participants working with IBM include EPRI and the University of Illinois Urbana-Champaign (U. of I.) to explore how quantum optimization algorithms could lead to more efficient power grids. Additionally, research institutions and national labs such as Fermilab are working with IBM in Illinois to accelerate high-energy physics research with quantum and advance technologies for distributed quantum computing. IBM is also teaming with leading universities such as the University of Chicago and U. of I. to push technological progress in quantum computing. For example, IBM and the University of Chicago recently demonstrated quantum advantage over leading classical methods using an approach with guaranteed correctness. Now, IBM's quantum computing technology is being brought physically into Chicago. Through NQAC, the new quantum computer will empower Illinois' quantum community to develop new algorithms and applications that will translate to real-world impact. And it will serve as a catalyst for developing Illinois' current and future quantum workforce. Earlier this year, IBM announced it would establish the FutureNow Chicago center at the IQMP in partnership with City Colleges of Chicago, to bring 750 jobs to the region across AI, cybersecurity, data science, quantum computing and other technologies. With the arrival of IBM Quantum System Two, Chicago and the State of Illinois will be cemented as a leading destination for quantum innovation, industrialization, and workforce development. Supporting Quotes "IBM's continued partnership and the unveiling of IBM Quantum System Two mark an exciting moment for the industry and our state's quantum ecosystem," said Brad Henderson, CEO of P33. "Deepening collaboration between industry, our universities, national labs, and state government is what sets us apart and further cements Illinois as a global leader in quantum technology." "We are proud to contribute the University of Illinois Urbana-Champaign's expertise and decades of leadership in supercomputing alongside our higher education and corporate partners," said Illinois Chancellor Charles L. Isbell, Jr. "As a public-serving university, Illinois' mission is to advance education, research, and economic opportunity across the state, and we're excited to engage in work that translates the brilliance of Illinois faculty into tangible, real-world impact that affirms the state of Illinois and Chicago as the epicenter of the next generation of technological progress." "This is a significant milestone in advancing Illinois' quantum economy and turning our state's world-class research capabilities into real-world economic opportunity," said Illinois Department of Commerce and Economic Opportunity Director Kristin Richards. "Through the State's leadership and strategic investments in quantum, we are building an ecosystem for long-term industry growth, new business investment, and high-quality jobs." IBM is a leading global hybrid cloud and AI, and business services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM's legendary commitment to trust, transparency, responsibility, inclusivity and service. Media contacts: SOURCE IBM
AbbVie's stock trades at 49.3 times trailing earnings, against 22.9 for the S&P 500. On management's 2026 adjusted earnings forecast, the multiple is about 21. The question is whether double-digit sales growth continues. Revenue rose 10.3% in the third quarter from a year earlier. AbbVie expects revenue of about $67.8 billion in 2026, up from $61.2 billion in 2025. Skyrizi and Rinvoq are adding $6 billion in sales in 2026 and should bring in $32.1 billion together, close to half of total sales. In 2027, a US government-set price under the Inflation Reduction Act (IRA) starts on Vraylar, which AbbVie expects to earn $4.2 billion in 2026. Management expects top-tier growth in 2027 and will give a forecast on its fourth-quarter call, expected in February 2027.
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, IL
Founded
1888
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs